Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.15 USD | +0.42% | -19.66% | +386.39% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Neutral | Bullish | Bullish |
Resistance | 14.00 | 14.00 | 11.50 |
Spread/Res. | -48.93% | -48.93% | -37.83% |
Spread/Supp. | +11.89% | +110.91% | +167.79% |
Support | 6.390 | 3.390 | 2.670 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- CADL Stock
- Charts Candel Therapeutics, Inc.